A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure - Dargie, H J; Hildebrandt, P R; Riegger, G A (J Am Coll Cardiol, 2007)
et al.